AI Summary
We reviewed 253 live results for biosimilar pharmaceutical and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Pharmaceuticals.
Comparison Table
Recommended
Steqeyma (ustekinumab biosimilar)
Source: Celltrion Healthcare
Description
Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL).
Best for
subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users
View Details
Rating
Bevacizumab Biosimilar
Source: Biocon Biologics Philippines Inc.
Description
An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients.
Best for
solid tumor treatment, cancer therapy and oncology clinics
Tags
View Details
Rating
Trastuzumab Biosimilar
Source: Biocon Biologics Philippines Inc.
Description
A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018.
Best for
HER2-positive breast cancer, gastric cancer treatment and oncology therapy
View Details
Rating
| Compare | Steqeyma (ustekinumab biosimilar) | Bevacizumab Biosimilar | Trastuzumab Biosimilar |
|---|---|---|---|
| Source | Celltrion Healthcare | Biocon Biologics Philippines Inc. | Biocon Biologics Philippines Inc. |
| Description | Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL). | An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients. | A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018. |
| Best for | subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users | solid tumor treatment, cancer therapy and oncology clinics | HER2-positive breast cancer, gastric cancer treatment and oncology therapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Steqeyma (ustekinumab biosimilar) from Celltrion Healthcare."
I picked this because Steqeyma is a recently HSA-approved biosimilar in Singapore that will soon offer enhanced affordability through government drug subsidies.
Share this search
Related Finds